Sanofi India Standalone December 2021 Net Sales at Rs 687.90 crore, down 4.5% Y-o-Y
NULL24-02-2022
Sanofi India Ltd - 500674 - Fixes Book Closure for Dividend & AGM
Sanofi India Ltd has informed BSE that the Register of Members & Share Transfer Books of the Company will remain closed from April 16, 2022 to April 26, 2022 (both days inclusive) for the purpose of Payment of Final Dividend (including Special Dividend) & Annual General Meeting (AGM) of the Company to be held on April 26, 2022.24-02-2022
Q3FY22 Quarterly Result Announced for Sanofi India Ltd.
Pharmaceuticals firm Sanofi India declares Q3FY22 result: The full year PAT increased by 98% from Rs 4,776 million in 2020 to Rs 9,444 million in 2021. The Company approved final dividend of Rs. 490 per share, which includes a special dividend of Rs 309 per share. The total revenue for the year 2021 stood at Rs. 29,566 million with a year-on-year growth of 2%. The domestic business delivered a strong growth of 13% (excluding the impact of the divestment transactions.) The Company delivered on its commitment to drive operational efficiencies, enhance digital capabilities and reinvent ways of working. The divestment of the Company’s nutraceuticals’ business in Q3 2021 and the sale of its’ Ankleshwar Site in Q2 2020 have also contributed to the lower operational cost. The profit before tax increased from Rs. 6,772 million in the year 2020 to Rs 12,576 million in the year 2021, an increase of Rs 5,804 million, on account of profit from sale of the nutraceuticals’ business of Rs 4,892 million in 2021 and increase in operating profit. The return on capital employed was 34.6% (without exceptional items) as compared to 34% in previous year. Rajaram Narayanan Managing Director, Sanofi India Limited “We have continued to grow our business in key therapies, while transforming our operations in all areas of the company. Despite the pandemic, our employees have been relentless in serving our patients and customers. Our solid 13% domestic market growth is testimony to their efforts. Recently the Sanofi group has launched a new brand identity that better represents who we are today i.e., a modern healthcare company bringing together dedicated talented people and cutting-edge science to transform the practice of medicine. Our purpose is to chase the miracles of science to improve people’s lives.” Result PDF24-02-2022
Sanofi India Ltd - 500674 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Please find enclosed copies of the Postal Ballot Notice of the Company published today, in newspapers, Business Standard and Sakal.23-02-2022
Sanofi India Ltd - 500674 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Company will hold an investor call on 2nd March 2022 at 2.00 p.m. The details of the Investor Call are as enclosed23-02-2022
Sanofi India Ltd - 500674 - Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/s
The Board of Directors of the Company at its Meeting held today, subject to the approval of the shareholders at the 66th Annual General Meeting, recommended the re-appointment of M/s. Price Waterhouse & Co. Chartered Accountants LLP as Statutory Auditors for a period of five years, from the conclusion of the Sixty-sixth AGM, until the conclusion of the seventy-first AGM of the Company. The brief profile of M/s. Price Waterhouse & Co. Chartered Accountants is enclosed:23-02-2022
Sanofi India Ltd - 500674 - Corporate Action-Board approves Dividend
We refer to our letter dated 7th February 2022 informing you of our Board Meeting that was scheduled today. The Meeting of Board of Directors commenced at 2.30 p.m. and concluded a 6.15 p.m. The following items were considered and approved: 1. Recommendation for payment of a final dividend of Rs.181 per equity share of Rs. 10 each for the year ended 31st December 2021 and a special dividend of Rs. 309 per equity share of Rs.10 each for the year ended 31st December 2021, after considering the slump sale and transfer of Company's nutraceuticals business during the year and reviewing the cash requirements for the Company's operations. 2. Closure of Register of Members and Share Transfer Books from for determining the eligibility of shareholders for payment of the final dividend and the special dividend.23-02-2022
Sanofi India Ltd - 500674 - Board Meeting Outcome for Audited Financial Results For The Quarter And Year Ended 31St December 2021
We refer to our letter dated 7th February 2022 informing you of our Board Meeting that was scheduled today. The meeting of Board of Directors commenced at 2.30 p.m. and concluded at 6.15 p.m. The Board approved audited financial results for the quarter and year ended 31st December 2021. Sanofi India Ltd We enclose a copy of the auditor's report and audited financial results of the Company for the quarter and year ended 31st December 2021 along with statement of assets and liabilities as on that date and statement of cashflows for the year ended 31st December 2021 along with press release as required under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for your information.23-02-2022
Sanofi India Ltd - 500674 - Shareholder Meeting / Postal Ballot-Notice of Postal Ballot
Further to our letter dated 15th February 2022, filing the Notice of Postal Ballot, this is to inform that the Company is seeking approval of Members of the Company through an Ordinary Resolution for Material Related Party Transaction(s) with Sanofi Healthcare Private Limited, a Related Party as per the Listing Regulations and other applicable law, as detailed in the Postal Ballot Notice dated 14th February 2022. The Company has today, 22nd February 2022, sent an e-mail through Link Intime India Private Limited, Registrar and Share Transfer Agents (RTA) of the Company, along with the Login ID and password to the Members for e-voting who have registered their e-mail id''s with Depository Participant(s) or with the Company. The voting period will commence from Wednesday,23rd February 2022, IST at 9.00 a.m. and will end on Thursday, 24th March, 2022 IST at 5.00 p.m.22-02-2022